Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H44O9 |
| Molecular Weight | 548.665 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1C[C@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C6=CC(=O)OC6)O[C@H](C)[C@H]1O
InChI
InChIKey=XQCGNURMLWFQJR-ZNDDOCHDSA-N
InChI=1S/C30H44O9/c1-17-26(33)23(36-3)13-25(38-17)39-19-4-9-28(16-31)21-5-8-27(2)20(18-12-24(32)37-15-18)7-11-30(27,35)22(21)6-10-29(28,34)14-19/h12,16-17,19-23,25-26,33-35H,4-11,13-15H2,1-3H3/t17-,19+,20-,21+,22-,23+,25+,26-,27-,28+,29+,30+/m1/s1
| Molecular Formula | C30H44O9 |
| Molecular Weight | 548.665 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/3821940
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3821940
Cymarin (or cymarine or k-strophanthidin-alpha) is a cardiac glycoside and an anti-arrhythmia and cardiotonic agent. Cymarin works as an inhibitor of Na+ /K+-ATPase . This inhibition has an inotropic effect on the cardiac muscles increasing their force by approximately 100%.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6146536 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3821940
Unknown
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:22:16 GMT 2025
by
admin
on
Mon Mar 31 19:22:16 GMT 2025
|
| Record UNII |
UK3LS8435E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
C01AC03
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
||
|
WHO-VATC |
QC01AC03
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D003529
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
208-087-9
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
DB13240
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
DTXSID20871714
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
m4028
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
508-77-0
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
CYMARIN
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL1651908
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
7522
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
441853
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
UK3LS8435E
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY | |||
|
4408
Created by
admin on Mon Mar 31 19:22:16 GMT 2025 , Edited by admin on Mon Mar 31 19:22:16 GMT 2025
|
PRIMARY |